Intralymphatic bcg in the treatment of gynecologic malignancies.A phase I study

Mangan, Charles E.; Jeglum, K A; Sedlacek, Thomas V.; Giuntoli, Robert L.; Wheeler, James E.; Rubin, Elizabeth S.; Mikuta, John J.

doi:10.1002/1097-0142(197712)40:6<2933::aid-cncr2820400627>3.0.co;2-j

Cited by 5 publications

(4 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since the regional lymph nodes are involved in the initiation of systemic immunity, immunomodulators may act more efficiently as immunogens when administered intra¬ lymphatically (11)(12)(13)(14)(15). Although the intralymphatic route has been used in (1)(2)(3)(4). This study was undertaken to examine a nonspecific immunostimulant BCG in a tumor system analogous to the cancer patient with measurable tumor burden and lymph node metastasis.…”

Section: Discussionmentioning

confidence: 99%

“…BCG was selected in this study due to its common usage in humans and our previous experimental and clinical experience with intralymphatic BCG (3,16). The V2 carcinoma in NZW rabbits was used in this study to represent a lymph node metastasizing solid tumor that kills via distant metastasis.…”

Section: Discussionmentioning

confidence: 99%

“…The direct delivery of biological response modifiers via intra¬ lymphatic injection in cancer patients has been reported (1)(2)(3) (4)(5)(6).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Enhanced Antitumor Effects with Intralymphatic Delivery Using Bacillus Calmette-Guerin in Animal Models

Jeglum¹,

Mangan²,

Wheeler³

1985

Cancer Drug Delivery

View full text Add to dashboard Cite

This study compares the effectiveness of various routes of administration of Bacillus Calmette-Guerin (BCG) utilizing the New Zealand white (NZW) rabbit V2 carcinoma model. The routes compared were intratumor, intravenous, scarification, subcutaneous, and intralymphatic. Primary tumor regression, disease-free interval, and survival were measured. The disease-free interval and survival for the intralymphatic group were significantly longer (p less than 0.05) than all groups except the scarification group. That group had a prolonged survival as compared with all groups except the intralymphatic group. The intralymphatic route of administration was the most effective method in causing local tumor regression and curtailing metastasis. This study clearly demonstrates that the intralymphatic route requires further mechanistic studies and clinical investigation as a means for delivering biological response modifiers.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Enhanced Antitumor Effects with Intralymphatic Delivery Using Bacillus Calmette-Guerin in Animal Models

Jeglum¹,

Mangan²,

Wheeler³

1985

Cancer Drug Delivery

View full text Add to dashboard Cite

show abstract

“…The routes and methods of administration include oral [5], IV [16,18], intralymphatic [25], intratumoral [28,29,30,32], ID [3], Heafgun technique [33], the tine plate method [28], scarification [3,7,8,9], and intrapleural [23,24]. 1 Several routes, schedules, doses and sources of BCG have been used in these various clinical trials.…”

Section: Discussionmentioning

confidence: 99%

Active specific immunotherapy of residual micrometastasis

Hanna

Brandhorst

Peters

1979

Cancer Immunol Immunother

View full text Add to dashboard Cite

A vaccine of Bacillus Calmette-Gu~rin (BCG) admixed with tumor cells induced systemic immunity and had a therapeutic effect on subclinical, disseminated mierometastasis. Inbred strain-2 guinea-pigs given I V injections of 5 x 103 to 106 syngeneic LIO hepatocarcinoma cells were vaccinated after metastatic foei were established in the lung parenchyma. The purpose of this study was to establish the variables that can be manipulated to assure optimal immunotherapy while minimizing deleterious side effects of the BCG. In the present study we examined the variables of source, dose, and ratio of BCG to tumor cells. Four BCG sources (lyophilized Tiee and Connaught; fresh-frozen Phipps and Tice) were compared. No significant differences among these BCG preparations couM be detected with respect to adjuvant potential when they were admixed with attenuated tumor cells in a vaccine. The dose study clearly demonstrated that a BCG dose dependency exists with relation to induction of effective cell-mediated immunity or survival from disseminated mierometastatic disease. Furthermore, evaluations of dose versus ratio of BCG to tumor cells also supported a BCG dose dependency, with the lowest effective BCG dose being directly influenced by tumor burden of the host. Cutaneous reactivity and hypersensitivity of the primary and secondary immunization sites of tumor-bearing animals treated with effective and ineffective vaccines supported the direct association of reaction to BCG and specific tumor immunity. However, when an in vitro leukocyte migration inhibition assay was used, the degree of reactivity to BCG could not be exploited as a quantitative, diagnostic monitor of effective systemic tumor immunity.

show abstract

Active specific immunotherapy of established micrometastases with BCG plus tumor cell vaccines: Effective treatment of BCG side effects with isoniazid

Hanna

Pollack

Peters

et al. 1982

Cancer

View full text Add to dashboard Cite

Intradermal vaccinations with Bacillus Calrnette-Gutin (BCG) and viable but nontumorigenic syngeneic hepatocarcinoma cell vaccines were used successfully to treat micrometastatic disease experimentally induced in inbred guinea pigs at 100 times the minimal lethal dose. Several complications have been associated with the use of viable BCC organisms in the treatment of cancer patients and, in this animal model, intradermal administration of BCG uniformly results in severe ulceration and eschar formation at the injection sites leading to secondary microbial invasion and regional lymphadenopathy. We now report the use of isoniazid (Nydrazid") as part of an active specific immunization regimen. Incorporation of isoniazid into the immunization procedure for two weeks alleviates or reduces the side effects of BCG infection. Moreover, with proper consideration of BCC dosage, isoniazid does not impair the efficacy of the BCC plus tumor cell vaccines. Cancer 49659-664, 1982. REVIOUS STUDIES from our laboratory have de

show abstract

Intralymphatic bcg in the treatment of gynecologic malignancies.A phase I study

Cited by 5 publications

References 20 publications

Enhanced Antitumor Effects with Intralymphatic Delivery Using Bacillus Calmette-Guerin in Animal Models

Enhanced Antitumor Effects with Intralymphatic Delivery Using Bacillus Calmette-Guerin in Animal Models

Active specific immunotherapy of residual micrometastasis

Active specific immunotherapy of established micrometastases with BCG plus tumor cell vaccines: Effective treatment of BCG side effects with isoniazid

Contact Info

Product

Resources

About